(Q48523529)

12 February 2018

title

Plasma levels of neuropeptides in Alzheimer's disease. (English)

1 reference

12 February 2018

0 references

6

1 reference

12 February 2018

author name string

Caterina Proto

1

1 reference

12 February 2018

Daniela Romualdi

2

1 reference

12 February 2018

Rosa Maria Cento

3

1 reference

12 February 2018

Rosario S Spada

4

1 reference

12 February 2018

Giuseppina Di Mento

5

1 reference

12 February 2018

Antonio Lanzone

7

1 reference

12 February 2018

publication date

1 April 2006

1 reference

12 February 2018

Gynecological Endocrinology

published in

1 reference

12 February 2018

volume

22

1 reference

12 February 2018

issue

4

1 reference

12 February 2018

page(s)

213-218

1 reference

12 February 2018

The origins of Alzheimer disease: a is for amyloid.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Hormonal control of the neuropeptide Y system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Novel neuropeptide Y processing in human cerebrospinal fluid from depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Neuropeptide Y. A novel sympathetic stress hormone and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Ghrelin induces adiposity in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

The role of the somatotropic system in cognition and other cerebral functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Anorexia, sarcopenia, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Cerebral blood flow in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Verbal and Non-Verbal Short-Term Memory Impairment Following Hemispheric Damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

A new Alzheimer's disease interventive strategy: GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Plasma neuropeptide Y is reduced in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Endocrinology of anorexia of ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

Screening Tests for Geriatric Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

The Global Deterioration Scale for assessment of primary degenerative dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500519385

10.1080/09513590500519385

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

PubMed ID

16723308

1 reference

12 February 2018